MedTrace Logo

Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)

NCT02433795 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2026-04-22

Study results available
· View outcomes & findings →

Summary

This study will be conducted to evaluate the efficacy of Bendamustine Plus Rituximab (BR) in patients with relapsed or progressive Marginal Zone B-cell Lymphoma (MZBCL).

Conditions

  • Marginal Zone B-cell Lymphoma

Interventions

DRUG

bendamustine plus rituximab

Bendamustine 90mg/m2 IV on days 1-2 up to 6th cycle Rituximab 375mg/m2 IV on day 1 at 1st cycle Rituximab 1400mg SC on day 1 from 2nd cycle every 4 weeks up to 8th cycle

Sponsors & Collaborators

  • Gyeongsang National University Hospital

    collaborator OTHER

  • Korea Cancer Center Hospital

    collaborator OTHER

  • Seoul National University Boramae Hospital

    collaborator OTHER

  • Hallym University Medical Center

    collaborator OTHER

  • Inje University

    collaborator OTHER

  • Gangnam Severance Hospital

    collaborator OTHER

  • Chonbuk National University Hospital

    collaborator OTHER

  • Chungnam National University

    collaborator OTHER

  • The Catholic University of Korea

    collaborator OTHER

  • Wonju Severance Christian Hospital

    collaborator OTHER

  • Gachon University Gil Medical Center

    collaborator OTHER

  • Seoul National University Bundang Hospital

    collaborator OTHER

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Dae Seog Heo, MD, PhD · Seoul National University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2019-10-31
Completion
2019-10-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02433795 on ClinicalTrials.gov